Trials / Recruiting
RecruitingNCT07253259
A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to evaluate the safety and efficacy of GT729 universal cell injection in the treatment of refractory or relapsed chronic graft-versus-host disease (cGVHD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT729 Injection | GT729 Injection |
Timeline
- Start date
- 2025-12-18
- Primary completion
- 2027-11-30
- Completion
- 2028-12-31
- First posted
- 2025-11-28
- Last updated
- 2026-04-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07253259. Inclusion in this directory is not an endorsement.